Heartflow turns coronary CT into AI analysis of anatomy, plaque and blood flow

Heartflow applies AI and physiological modeling to coronary computed tomography angiography, or CCTA. Its Heartflow One platform brings together information about coronary anatomy, plaque and blood flow for qualified clinicians. For a health system, the purchase is an imaging analysis service connected to an existing coronary program. Its value depends on the right studies reaching the right analysis and on clinicians receiving usable results within their established review process.

01 / ProductThree views of coronary disease belong in one case

Heartflow One organizes several related products around the same scan. Roadmap Analysis supports the anatomical reading, Plaque Analysis characterizes disease burden, and FFRCT Analysis adds physiological information. These outputs answer different questions. An anatomical narrowing, a quantity of plaque and a modeled pressure relationship should not be collapsed into a single generic AI result. The platform brings them into a shared patient context without making them interchangeable.

The FFRCT product description explains that deep learning and computational fluid dynamics contribute to a patient-specific model. This is a specialized application of AI to medical images and simulation, rather than a language model summarizing a report. The resulting coronary model presents calculated values that clinicians can inspect alongside the scan. Sequenced has not run an independent clinical evaluation of those calculations.

Plaque Analysis addresses a different aspect of the examination: the amount and composition of plaque. Its interactive presentation includes related three-dimensional, vessel and cross-sectional views, with a downloadable report. The operational benefit of related views is traceability. A reviewer can move from an aggregate description to the relevant location instead of receiving an unexplained score detached from the source anatomy.

02 / AudienceCoronary programs are the natural organizational buyer

Heartflow is most relevant to cardiology and radiology services that already perform, or are establishing, appropriate CCTA workflows. Imaging technologists, interpreting clinicians, IT and reimbursement staff each own a different dependency. A department can be interested in the model while still lacking the operational capacity to acquire suitable scans, transmit them consistently and ensure results reach the responsible physician.

The comparison with Cleerly is useful because both sit close to coronary CT analysis, with product-specific differences that deserve a direct evaluation. Aidoc offers a broader view of clinical imaging AI orchestration. Neither comparison establishes a winner. It helps buyers decide whether they are evaluating detailed coronary assessment or a wider enterprise imaging workflow.

A general AI development team seeking downloadable weights is a less natural audience. The public offer is a clinical analysis platform with defined intended uses and implementation support. Likewise, a consumer seeking an immediate interpretation of an uploaded scan would be asking for a different access model. The workflow described here assumes a qualified healthcare organization and the appropriate professional review, rather than self-service diagnosis.

03 / WorkflowA proposed evaluation follows the scan through the organization

Begin a proposed operational pilot with the institution's imaging and clinical leads agreeing which currently supported analysis they intend to evaluate. Identify a permitted retrospective dataset and the relevant product version. Have the team map its ordinary acquisition and reporting process before adding the service. This establishes where a new result would arrive and which existing decision it is meant to inform.

Next, trace an eligible CCTA from the scanner or archive through the configured transfer. Confirm that identifiers, study dates and series remain associated with the correct case. Review how duplicate transmissions and incomplete studies are handled. These checks examine whether the system can deliver the intended service; they do not establish clinical accuracy or justify changing a patient's treatment.

For a completed case, inspect each requested output separately. The platform page notes that FFRCT and Plaque analyses are shown only when specifically requested, and that PACS and electronic medical record integration is optional. Therefore, a proposed pilot should include the actual order configuration and delivery destination. An absent analysis can reflect scope or configuration, rather than a clinical finding.

Then follow the handoff to the interpreting professional. Determine whether they can identify the source examination, inspect the output and document their interpretation without creating an untracked parallel record. Record the time between successful transmission and usable delivery in the local workflow. A vendor-reported median turnaround is not a deadline that automatically applies to every site or every submitted examination.

The support offering includes help with image quality, workflow, technology integration and reimbursement. Use that support to resolve a realistic failure case: an unsuitable scan, missing output or delivery interruption. A successful pilot should make unsuccessful processing visible. It should also specify who receives the exception and how normal clinical work continues while the issue is resolved.

04 / PricingProvider payment is different from the price of analysis

Heartflow publishes reimbursement resources for US care settings. Those resources describe coding and payment pathways, including separate treatment of hospital outpatient and physician office settings. They are not a retail tariff for Heartflow One, and a displayed reimbursement amount is not the amount a particular institution will pay Heartflow or collect from a payer.

The reviewed product and support pages route interested organizations into a commercial discussion rather than publishing a universal subscription price. Obtain a proposal covering the analyses requested, implementation, delivery interfaces and support. Clarify whether charges follow submitted, accepted or completed studies and how reprocessing is treated. These are questions to resolve in the agreement, not pricing rules established by the public pages.

A useful financial comparison keeps three quantities separate: the service's contracted cost, the organization's implementation and operating effort, and any applicable reimbursement. The third depends on the setting, payer and supporting documentation. The reimbursement page also mixes a current calendar-year table with a historical code-transition note, so local coding staff should verify the applicable code and policy before building a forecast.

05 / DistinctionsAnatomy and physiology can be reviewed together

Heartflow's substantive distinction is the combination of complementary outputs around the same CCTA. A team does not have to regard plaque characterization and physiology as rival descriptions of disease. Each can contribute a different perspective to the clinician's assessment. The editorial inference is that coherent case presentation may be more useful than separately optimized tools when the receiving workflow needs several kinds of information together.

Integration also deserves weight in a comparison. A capable analysis delivered into a rarely checked portal can create a different workload from the same information delivered into the institution's established reading environment. Conversely, an interface alone is insufficient if the local order does not request the intended analysis. The buyer should demonstrate the complete relationship between ordering, processing and review rather than treating connectivity as a yes-or-no feature.

The company's pages include strong claims about clinical and economic effects. Those claims belong to the cited studies and their populations, comparators and assumptions. This blueprint does not convert them into a universal accuracy rate or a promised financial return. A procurement discussion should examine evidence for the actual product and workflow being purchased, including results that do not fit the headline summary.

06 / QuestionsIntended use and image suitability set real limits

The current indications page describes analysis of previously acquired CT DICOM data and identifies qualified clinicians as users. Its combined-product description applies to adults aged 22 and older with suspected coronary artery disease. The page also separates FFRCT-only sites and lists unevaluated populations and image-related precautions. Those distinctions are more specific than the platform's broad coronary-care description.

Product availability also varies by jurisdiction. The website says the analyses and PCI Navigator are commercially available in the United States, with particular functionality available in selected other regions. An institution outside the US should establish the locally available product and documentation rather than assuming every module shown on the US site is included. The same principle applies when expanding an existing installation.

Another unresolved question is how the chosen configuration handles images that cannot support a particular analysis. The team should request the relevant acceptance criteria and examine the resulting operational status during evaluation. A technical rejection, an analysis that was never ordered and a successfully processed case without a particular finding are different states. Users need enough visibility to avoid mistaking one for another.

07 / DecisionDecide around a specific coronary workflow

Heartflow is a substantial AI-related company because its core product applies machine learning and modeling to an established clinical imaging task. A sensible evaluation starts with one defined coronary program and follows its complete data and reporting path. The decision should rest on demonstrated local fit, applicable evidence and a clear commercial agreement, with professional interpretation remaining central.

Expansion becomes easier to assess once the institution knows which analyses are routinely requested, where exceptions occur and whether results are available when clinicians need them. Adding more modules or sites should preserve those checks. The most useful purchase is the combination of analysis and workflow support that the organization can actually operate consistently, rather than the largest collection of advertised capabilities.